Eyenuk received $25 million in Series A funding to expand access to its AI-powered eye-screening technology that enables autonomous detection of diabetic retinopathy (DR) during a patient's regular exam.
The recent raise was led by AXA IM Alts and joined by new and existing investors, including A&C Foelsgaard Alternativer ApS, T&W Medical A/S, KOFA Healthcare and Kendall Capital Partners...
